Written by Chris Hellmund, Senior Medical Writer Origins of the Highly Specialised Technologies (HST) process Treatments for very rare conditions represent a unique challenge to payers. Extremely low patient numbers mean that often only Phase 1/2 trial data are...
Written by Neil Webb (Head of Systematic Review) and Chris Hellmund (Senior Medical Writer) On the 1st April 2017, the National Institute for Health and Care Excellence (NICE) introduced a fast-track appraisal (FTA) process, with the aim of providing quicker access...
Written by David Trueman, Director The rate at which future costs and outcomes are discounted has long stood at 3.5% for UK HTA agencies (1,2). The source of this discount rate is the Social Time Preference Rate (STPR), presented in previous versions of the Treasury’s...
Written by Julie Fricke (Systematic Review Analyst) and Neil Webb (Head of Systematic Review) As described in the Cochrane Collaboration Handbook, a systematic literature review (SLR) attempts to collate all empirical evidence that fits pre-specified eligibility...
Written by Elise Elvers, Health Economist The Boston-based Institute for Clinical and Economic Review, otherwise known as ICER, has caught the attention of important stakeholders in the past few years. Between reports for high-impact drugs that have stirred public...
